Second Time's The Charm: Novartis' New Bid Lures Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron's vaccines unit will operate as a separate division while its biopharmaceuticals unit will merge with Novartis' pharmaceutical business.
You may also be interested in...
Flu Vaccine 2006-2007 Strains To Be Determined By Advisory Cmte. Feb. 17
The committee will hold annual meeting to decide the influenza strains for the upcoming flu season.
Flu Vaccine 2006-2007 Strains To Be Determined By Advisory Cmte. Feb. 17
The committee will hold annual meeting to decide the influenza strains for the upcoming flu season.
Chiron Minority Shareholder Will Oppose Novartis Takeover
Shareholder ValueAct Capital owns 5% of Chiron's shares and 9% of non-Novartis-owned shares.